Doug Cole joined Flagship Pioneering in 2001. He focuses on life science.
At Flagship, Doug has co-founded Ensemble Therapeutics, Foghorn Therapeutics (NASDAQ: FHTX), Inzen Therapeutics, Moderna (NASDAQ: MRNA), Permeon Biologics, Sigilon Therapeutics, (NASDAQ: SGTX), and Syros Pharmaceuticals (NASDAQ: SYRS). He has led investments in Agios Pharmaceuticals (NASDAQ: AGIO), Alvine Pharmaceuticals, Avedro (NASDAQ: AVDR, acquired by Glaukos), CombinatoRx (NASDAQ: ZLCS), Concert Pharmaceuticals (NASDAQ: CNCE), Denali Therapeutics (NASDAQ: DNLI), Editas (NASDAQ: EDIT), Quanterix Corporation (NASDAQ: QTRX), Receptos (NASDAQ: RCPT, acquired by Celgene), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ: TTPH), and Torque.
He currently serves on the board of directors of Denali Therapeutics, Foghorn Therapeutics, KSQ Therapeutics, Harbinger Health, Repertoire Immune Medicines, Sana Biotechnology (NASDAQ: SANA), Sigilon Therapeutics, and Sonata Therapeutics. He formerly served on the board of directors of Avedro, AVEO Oncology (NASDAQ: AVEO), CombinatoRx, Concert Pharmaceuticals, CGI, Moderna, Morphotek (acquired by Eisai Pharmaceuticals), Receptos, Resolvyx, Selecta (NASDAQ: SELB), Seventh Sense, Taris (acquired by JNJ), and Tetraphase.
Before joining Flagship, Doug was instructor in neurology at Harvard Medical School and assistant in neurology at the Massachusetts General Hospital; medical director at Cytotherapeutics, in Providence, Rhode Island; and program executive at Vertex Pharmaceuticals, Inc., in Cambridge, Mass.
He holds an A.B. magna cum laude with high distinction in English from Dartmouth College, where he was a senior fellow and a member of Phi Beta Kappa, and an M.D. from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, and in neurology at the Massachusetts General Hospital in Boston, Mass.
Doug is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.